The story previously reported that the test being evaluated is from Rheonix and is based on its CARD technology. In fact, Mayo is developing its own test based on IP from Rheonix but not based on the CARD technology.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Mayo Clinic said on Monday that it has reached an agreement with Rheonix to collaborate on evaluating the performance of a genotyping test for warfarin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.